All In Biotech

Drug Trial Radar · NCT06770465

Maternal Use of Antibiotics and the Risk of Congenital Malformations

Maternal Use of Antibiotics and the Risk of Congenital Malformations: a Study Using Spontaneous Reporting Data and a Population-based Cohort Data From the US, Canada and China

Last checked: Nov 19, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

850,000

Actual

Start

Jun 1, 2024

Primary completion

Jun 30, 2025

Study completion Jun 30, 2026

Sponsor

Lead sponsor
West China HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 13, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Female only, from 14 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Antibiotics are widely used during pregnancy to prevent or treat infections, yet concerns remain regarding their fetal safety. Drawing on data from spontaneous reporting databases and cohort studies, this study aims to explore potential associations between exposure to various antibiotic classes during pregnancy and congenital malformations. Data were collected from publicly available reports in the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS), the Canada Vigilance Adverse Reaction (CVAR) database, and a population-based retrospective cohort in Xiamen, China. By applying multiple signal detection methods, we identified potential risk signals linking different antibiotic classes to organ-system-specific congenital malformations. For antibiotics showing positive signals, we further utilized a pregnancy medication cohort in Xiamen and applied causal inference techniques to estimate the adjusted relative risk of congenital malformations associated with first-trimester exposure to these antibiotics. Several sensitivity analyses-including both negative- and positive-control analyses-will also be performed.

Conditions

  • Congenital Malformations

Interventions

  • Different categories of antibioticsDrug

    Use of different categories of antibiotics during pregnancy, such as quinolones and macrolides.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Congenital malformationsTime frame: From pregnancy to 42 days after delivery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The West China Hospital of Sichuan university

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.